HRP20140447T1 - Cjepivo koje sadrži ekstrakt ribosomskog proteina (rpe) i opcionalni th-1 promovirajuä†i adjuvans - Google Patents

Cjepivo koje sadrži ekstrakt ribosomskog proteina (rpe) i opcionalni th-1 promovirajuä†i adjuvans Download PDF

Info

Publication number
HRP20140447T1
HRP20140447T1 HRP20140447AT HRP20140447T HRP20140447T1 HR P20140447 T1 HRP20140447 T1 HR P20140447T1 HR P20140447A T HRP20140447A T HR P20140447AT HR P20140447 T HRP20140447 T HR P20140447T HR P20140447 T1 HRP20140447 T1 HR P20140447T1
Authority
HR
Croatia
Prior art keywords
leishmania
ribosomal protein
protein extract
extract
use according
Prior art date
Application number
HRP20140447AT
Other languages
English (en)
Croatian (hr)
Inventor
Manuel Soto ÁLVAREZ
Daniel Ruiz ABÁNADES
Carlos Alonso Bedate
Original Assignee
Laboratorios Leti, S.L. Unipersonal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Leti, S.L. Unipersonal filed Critical Laboratorios Leti, S.L. Unipersonal
Publication of HRP20140447T1 publication Critical patent/HRP20140447T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/008Leishmania antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20140447AT 2008-01-18 2009-01-14 Cjepivo koje sadrži ekstrakt ribosomskog proteina (rpe) i opcionalni th-1 promovirajuä†i adjuvans HRP20140447T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2192808P 2008-01-18 2008-01-18
EP08100634 2008-01-18
PCT/EP2009/050334 WO2009090175A1 (en) 2008-01-18 2009-01-14 Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant

Publications (1)

Publication Number Publication Date
HRP20140447T1 true HRP20140447T1 (hr) 2014-07-04

Family

ID=39471089

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140447AT HRP20140447T1 (hr) 2008-01-18 2009-01-14 Cjepivo koje sadrži ekstrakt ribosomskog proteina (rpe) i opcionalni th-1 promovirajuä†i adjuvans

Country Status (19)

Country Link
US (1) US20110020405A1 (enExample)
EP (2) EP2231700B1 (enExample)
JP (2) JP2011509968A (enExample)
CN (1) CN101977930B (enExample)
AP (1) AP3007A (enExample)
AU (1) AU2009204849B2 (enExample)
BR (1) BRPI0906787A2 (enExample)
CA (1) CA2712475A1 (enExample)
CO (1) CO6280495A2 (enExample)
DK (1) DK2231700T3 (enExample)
ES (1) ES2486365T3 (enExample)
HR (1) HRP20140447T1 (enExample)
MA (1) MA32080B1 (enExample)
MX (1) MX2010007831A (enExample)
PL (1) PL2231700T3 (enExample)
PT (1) PT2231700E (enExample)
RU (1) RU2521499C2 (enExample)
WO (1) WO2009090175A1 (enExample)
ZA (1) ZA201005143B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
SG190222A1 (en) 2010-11-10 2013-06-28 Leti Sl Lab New adjuvant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500437B1 (en) * 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
PT1141305E (pt) * 1998-12-23 2006-10-31 Leti Lab Gene quimerico formado pelas sequencias de adn que codifica os determinantes antigenicos de quatro proteinas de l. infantum
ES2169995B1 (es) * 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US20030072714A1 (en) * 2001-10-12 2003-04-17 Magill Alan J. Microfluidized leishmania lysate and methods of making and using thereof

Also Published As

Publication number Publication date
RU2010134427A (ru) 2012-02-27
JP2015180638A (ja) 2015-10-15
EP2231700B1 (en) 2014-05-07
PL2231700T3 (pl) 2014-09-30
JP2011509968A (ja) 2011-03-31
MA32080B1 (fr) 2011-02-01
AP3007A (en) 2014-10-31
CN101977930A (zh) 2011-02-16
WO2009090175A1 (en) 2009-07-23
CA2712475A1 (en) 2009-07-23
EP2570427A1 (en) 2013-03-20
AP2010005333A0 (en) 2010-08-31
DK2231700T3 (da) 2014-07-14
AU2009204849A1 (en) 2009-07-23
PT2231700E (pt) 2014-07-31
CO6280495A2 (es) 2011-05-20
AU2009204849B2 (en) 2013-10-03
MX2010007831A (es) 2011-06-20
US20110020405A1 (en) 2011-01-27
HK1150291A1 (en) 2011-11-18
RU2521499C2 (ru) 2014-06-27
ES2486365T3 (es) 2014-08-18
ZA201005143B (en) 2011-12-28
BRPI0906787A2 (pt) 2015-08-18
EP2231700A1 (en) 2010-09-29
CN101977930B (zh) 2014-12-17

Similar Documents

Publication Publication Date Title
EA201490903A1 (ru) Композиции и способы лечения вирусного гепатита c
AR071917A1 (es) Vacunas contra la coccidiosis
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
WO2013098655A3 (en) Vaccines directed against human enteroviruses
UA114351C2 (uk) Поліциклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування
AR036125A1 (es) Vacuna de mycoplasma bovis metodos para reducir la neumonia en animales; procedimiento de preparacion de dicha vacuna y kit
HRP20220924T1 (hr) Imunoterapija zasnovana na pd-l1
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
CR10559A (es) Vacuna de influenza
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
BRPI0923448A2 (pt) vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina.
BRPI0720667A8 (pt) Métodos de administração de vacina
CO6430434A2 (es) Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
WO2012170753A3 (en) Bovine vaccines and methods
RU2015106791A (ru) Иммуногенные композиции
WO2013104995A3 (en) Compositions and methods for treating viral infections
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
ECSP066916A (es) Vacuna contra estreptococo agalactiae
MX391930B (es) Vacuna contra la fiebre aftosa.
AR088907A1 (es) Vacuna
MX2024006589A (es) Formulaciones de vacunas contra el coronavirus.
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
EA201592040A1 (ru) Иммуногенная композиция для применения в терапии
CO6280408A2 (es) Vacuna de virus de la lengua azul y composiciones inmunogenicas procedimientos de uso y procedimeintos de la produccuion de la misma